Recent Updates
Recently added Catalysts
EBS

Emergent BioSolutions to Participate in Cantor Fitzgerald Global Healthcare Conference

Thursday, September 26, 2019 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: GAITHERSBURG, Md., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s senior management team will participate in the Cantor Fitzgerald Global Healthcare Conference 2019 to be held in New York from October 2 to 4

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+70%
120-day peak, hindsight
Typical move
8%
average across 2 past catalysts
Lead asset
FLU-IGIV
Phase 2 · Influenza A H3N2

Full Press Release Details

GAITHERSBURG, Md., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s senior management team will participate in the Cantor Fitzgerald Global Healthcare Conference 2019 to be held in New York from October 2 to 4.
Presentation date and time will be updated on the Emergent website www.emergentbiosolutions.com under “Investors” as the information becomes available.
The company will be webcasting its presentation, which may include a discussion of the company's recent business developments as well as its most recently reported financial results and guidance. The webcast will be available both live and by replay, accessible from the Emergent website.
About Emergent BioSolutions
ShareAdd on Google
Tags: EBS Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Sep 26, 2019

Biotech snapshot

Cash runway
$141M liquidity · $0M/mo burn
Low dilution risk
Lead asset
FLU-IGIVPhase 2
Influenza A H3N2 →

Catalyst track record

+70%
best trade around EBS's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for EBS.

See every catalyst's timing & PoA →